Podcast Episodes
Back to Search
Episode 154: Eleanor Fox on Illumina’s FTC headache, plus Talkspace’s experiment
First, STAT’s Mario Aguilar joins us to discuss a fascinating experiment in Nevada, where one city is giving its residents free access to a therapy a…
5 years, 7 months ago
Episode 153: AstraZeneca and the very good, then quite bad, then deeply confusing week
We're devoting this week's episode to the week of whiplash news about AstraZeneca's Covid-19 vaccine, subject of a baffling international incident wi…
5 years, 7 months ago
Episode 152: Alison Buttenheim on Europe's vaccine scare, Lilly's Alzheimer's data, & a PR plea
First we unpack the crisis of confidence facing AstraZeneca's Covid-19 vaccine in Europe with Alison Buttenheim, a University Pennsylvania professor …
5 years, 7 months ago
Episode 151: Natasha Loder on Covid vaccines, the demise of Watson Health, and a 'synbio' explainer
We're joined by Natasha Loder, the health policy editor at The Economist — and a London resident — to get her home-country perspective on the U.K.'s …
5 years, 7 months ago
Episode 150: Ashish Jha on Covid-19 optimism, plus pharma cooperation, & the next pandemic phase
We discuss Merck's decision to help Johnson & Johnson manufacture vaccine doses and whether it'll be a turning point for the drug industry or a relic…
5 years, 7 months ago
Episode 149: Nancy Goodman on Covid vaccines for kids, & Greg Zuckerman on Novavax's remarkable rise
First, pediatric cancer advocate Nancy Goodman joins us to discuss why she believes Covid-19 vaccine trials need to be sped up for teens and children…
5 years, 8 months ago
Episode 148: Akshay Sharma on gene therapy's setback, biotech's brashest VCs, & the FDA's future
We discuss all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. First, we break down a significant setback for Bluebird Bio’s g…
5 years, 8 months ago
Episode 147: David Fajgenbaum on Covid-19 drugs, the state of the pandemic, & meme biotech stocks
When will we have enough vaccine doses? How many effective Covid-19 drugs are just waiting to be found? And what do Redditors think about biotech? We…
5 years, 8 months ago
Episode 146: Paul Offit on vaccine data, 23andMe is going public, & Merck's CEO is retiring
We discuss all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. First, we recap a busy week of news, featuring 23andMe's move t…
5 years, 8 months ago
Episode 145: Kevin Davies on the CRISPR boom, & Megan Ranney on scientific misinformation
First, we discuss the implications of Johnson & Johnson’s any-day-now data on a one-shot vaccine for Covid-19. Then, Kevin Davies, executive editor o…
5 years, 9 months ago